Collegium Pharmaceutical (COLL) Short term Debt (2014 - 2026)

Collegium Pharmaceutical's Short term Debt history runs 13 years deep, the most recent figure standing at $32.6 million for Q1 2026.

• In Q1 2026, Short term Debt fell 49.48% year-over-year to $32.6 million; the TTM figure through Mar 2026 stood at $32.6 million (down 49.48% YoY), while the FY2025 annual figure was $29.0 million, down 55.1% from the prior year.
• Short term Debt was $32.6 million for Q1 2026 at Collegium Pharmaceutical, up from $29.0 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $183.3 million in Q1 2023 to a low of $19000.0 in Q3 2025.
• Historically, Short term Debt has averaged $110.6 million across 5 years, with a median of $120.8 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Short term Debt surged 236.07% in 2022, then sank 99.98% in 2025.
• A 5-year view of Short term Debt shows it stood at $162.5 million in 2022, then advanced by 12.82% to $183.3 million in 2023, then slumped by 64.77% to $64.6 million in 2024, then slumped by 55.1% to $29.0 million in 2025, then rose by 12.5% to $32.6 million in 2026.
• The last three Short term Debt figures came in at $32.6 million (Q1 2026), $29.0 million (Q4 2025), and $19000.0 (Q3 2025), per Business Quant data.